Cargando…
Radioprotective effects of oral 17-dimethylaminoethylamino-17-demethoxygeldanamycin in mice: bone marrow and small intestine
BACKGROUND: Our previous research demonstrated that one subcutaneous injection of 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) 24 hours (h) before irradiation (8.75 Gy) increased mouse survival by 75%. However, the protective mechanism of 17-DMAG is currently unknown. The present st...
Autores principales: | Lu, Xinyue, Nurmemet, Dilber, Bolduc, David L, Elliott, Thomas B, Kiang, Juliann G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852109/ https://www.ncbi.nlm.nih.gov/pubmed/24499553 http://dx.doi.org/10.1186/2045-3701-3-36 |
Ejemplares similares
-
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors
por: Aregbe, Abdulateef O., et al.
Publicado: (2012) -
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells
por: Yao, Jia-Qi, et al.
Publicado: (2010) -
Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in transgenic mouse models of frontotemporal lobar degeneration and Alzheimer’s disease
por: Ho, Shuk Wai, et al.
Publicado: (2013) -
Effects of 17-allylamino-17-demethoxygeldanamycin on the induction of apoptosis and cell cycle arrest in HCT-116 cells
por: Zhao, Xuerong, et al.
Publicado: (2017) -
Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin
por: Wu, X, et al.
Publicado: (2009)